Web Focus on Cancer Immunotherapy
Exploiting and targeting the immune system are emerging as important therapeutic strategies for cancer.
Here we bring together recent papers covering experimental models as well as early phase human clinical studies and highlighting novel CTL epitopes, cellular therapy approaches, cancer vaccines, and anti–tumour immunoRNases
Immunotherapy augments the effect of 5-azacytidine on HPV16-associated tumours with different MHC class I-expression status Open
J Šímová, V Polláková, M Indrová, R Mikyšková, J Bieblová, I Št ě pánek, J Bubeník and M Reiniš
Br J Cancer 105: 1533-1541; advance online publication, October 20, 2011; doi:10.1038/bjc.2011.428
Expansion of anti-AFP Th1 and Tc1 responses in hepatocellular carcinoma occur in different stages of disease Open
S Behboudi, A Alisa, S Boswell, J Anastassiou, A A Pathan and R Williams
Br J Cancer 102: 748-753; advance online publication, January 19, 2010; doi:10.1038/sj.bjc.6605526
Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer Open
K Imai, S Hirata, A Irie, S Senju, Y Ikuta, K Yokomine, M Harao, M Inoue, Y Tomita, T Tsunoda, H Nakagawa, Y Nakamura, H Baba and Y Nishimura
Br J Cancer 104: 300-307; advance online publication, December 21, 2010; doi:10.1038/sj.bjc.6606052
Immune activation by combination human lymphokine-activated killer and dendritic cell therapy Open
E J West, K J Scott, V A Jennings and A A Melcher
Br J Cancer 105: 787-795; advance online publication, August 16, 2011; doi:10.1038/bjc.2011.290
The ganglioside antigen GD2 is surface–expressed in Ewing sarcoma and allows for MHC–independent immune targeting Open
S Kailayangiri, B Altvater, J Meltzer, S Pscherer, A Luecke, C Dierkes, U Titze, K Leuchte, S Landmeier, M Hotfilder, U Dirksen, J Hardes, G Gosheger, H Juergens and C Rossig
Br J Cancer 106: 1123-1133; advance online publication, February 28, 2012; doi:10.1038/bjc.2012.57
Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells Open
U Thiel, S Pirson, C Müller-Spahn, H Conrad, D H Busch, H Bernhard, S Burdach and G H S Richter
Br J Cancer 104: 948-956; doi:10.1038/bjc.2011.54
Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines Open
Y Wang, X-Y Wang, J R Subjeck, P A Shrikant and H L Kim
Br J Cancer 104: 643-652; advance online publication, February 1, 2011; doi:10.1038/bjc.2011.15
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial Open
G Procopio, E Verzoni, S Bracarda, S Ricci, C Sacco, L Ridolfi, C Porta, R Miceli, N Zilembo and E Bajetta on behalf of Italian Trials Medical Oncology (ITMO) study Group
Br J Cancer 104: 1256-1261; advance online publication, March 29, 2011; doi:10.1038/bjc.2011.103
Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours Open
A J Nicol, H Tokuyama, S R Mattarollo, T Hagi, K Suzuki, K Yokokawa and M Nieda
Br J Cancer 105: 778-786; advance online publication, August 16, 2011; doi:10.1038/bjc.2011.293
Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab Open
P Todeschini, E Cocco, S Bellone, J Varughese, K Lin, L Carrara, F Guzzo, N Buza, P Hui, D-A Silasi, E Ratner, M Azodi, P E Schwartz, T J Rutherford, S Pecorelli and A D Santin
Br J Cancer 105: 1176-1182; advance online publication, September 13, 2011; doi:10.1038/bjc.2011.369
A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours Open
M Borriello, P Laccetti, G Terrazzano, G D'Alessio and C De Lorenzo
Br J Cancer 104: 1716-1723; advance online publication, May 10, 2011; doi:10.1038/bjc.2011.146
Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours Open
T Gelardi, V Damiano, R Rosa, R Bianco, R Cozzolino, G Tortora, P Laccetti, G D'Alessio and C De Lorenzo
Br J Cancer 102: 513-519; advance online publication, January 5, 2010; doi:10.1038/sj.bjc.6605499
A phase 1 trial of recombinant human IL-21 in combination with cetuximab in patients with metastatic colorectal cancer Open
N Steele, A Anthony, M Saunders, B Esmarck, E Ehrnrooth, P E G Kristjansen, A Nihlén, L T Hansen and J Cassidy
Br J Cancer 106: 793-798; advance online publication, February 7, 2012; doi:10.1038/bjc.2011.599
partner of